After predicting that Moderna (MRNA) would have trouble trading at $100 a few months ago and then going nowhere next, readers may think this update will turn bearish.
It will not.
Investors should have expected the bearish selling on Moderna, Novavax (NVAX), and especially Sorrento (SRNE) and Inovio Pharmaceuticals (INO). Markets honed in their frenzied buying on the electric vehicle segment and cloud-computing technology stocks. Plus, clinical results from the vaccine players no longer give the biotechnology stocks a reason to bid shares higher. The “sell